Beleave Inc. (CNSX:BE) at the request of the Investment Industry Regulatory Organization of Canada wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.
Consistent with the Company’s press release dated September 26, 2016, the Company continues work with Health Canada towards the scheduling of a pre-licensing inspection of its proposed facility.
About Beleave Inc.
Beleave, Inc. is a biotech company committed to becoming a licensed producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“). Beleave’s wholly-owned subsidiary First Access Medical Inc. (“FAM“) has applied for a license to cultivate and sell medical marihuana pursuant to the ACMPR. As of the date hereof, FAM has successfully advanced past the review stage, and has been issued an affirmation letter from Health Canada prior to a request for a pre-licensing inspection. Beleave’s purpose-built facility is located near Hamilton, Ontario.
Forward-Looking Statements
This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the ACMPR licensing process and meeting the requirements of the ACMPR. No assurances are given as to the anticipated timing of delivering the confirmations to Health Canada described in this press release nor the anticipated timing of any pre-licensing inspection. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Connect with Beleave Inc. (CNSX:BE) to receive an Investor Presentation.
The potential for new disease research and treatments is expanding thanks to the global adoption of marijuana for medical purposes.
As more countries open the doors to the use and investigation of cannabis, medical applications for the drug are set to expand — indeed, the drug has already shown promise.
However, in terms of treating skin cancer patients, currently the promise of cannabis outpaces any medically confirmed results or applications.
Find out what experts say about profiting from the cannabis market in 2020!
Read our FREE 2020 cannabis outlook report!
So far marijuana and skin cancer have not been effectively paired up for a proper treatment, but the cannabis plant may offer options for patients once more clinical trials and research are confirmed.
Though there may be individual cases claiming to credit the drug, cannabis and its derivatives are not being applied for the treatment of skin cancer.
According to the American Cancer Society, skin cancer is the most common type of cancer, accounting for over 5 million cases per year. This category holds many different variations, but the main three types are basal cell carcinomas, squamous cell carcinomas and melanomas; the rest are considered rare.
Melanomas develop in specific areas like the neck and face and can be more serious than their counterparts. Basal and squamous cancer cells, on the other hand, are developed based on a person’s sun exposure and mostly develop in the head and neck.
The Canadian Cancer Society states that treatments of non-melanoma skin cancer include surgery, radiation therapy, photodynamic therapy and drug therapy, including the use of topicals.
Cannabis and cancer could be paired up as more research across the globe begins to take place, looking for new medications and formulations, boosted by the early successes of the drug.
While research is still lacking in the overall medical marijuana space, there have been serious improvements, such as GW Pharmaceuticals (NASDAQ:GWPH) obtaining approval in the US for its cannabidiol (CBD) solution, which treats seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in toddlers.
After going through its clinical trials, the company’s Epidiolex drug approval from the US Food and Drug Administration, signaling that top medical agencies are ready to confirm the medical prowess of cannabis and its derivatives for the benefit of patients.
Find out what experts say about profiting from the cannabis market in 2020!
Read our FREE 2020 cannabis outlook report!
Additionally, the National Eczema Association has vouched for CBD as an option in the treatment of eczema, a skin disease that affects over 30 million people in the US.
“It has long been observed that cannabinoids possess anti-inflammatory, antimicrobial and anti-itch qualities,” the Independent reported.
A study from the the University of Colorado School of Medicine is looking further into the use of CBD for patients with psoriasis or eczema who have tried using topical steroids or topical immunomodulators.
Robert Dellavalle, professor of dermatology with the University of Colorado, told Inside Science that CBD products are growing in popularity, but the results are not being collected as properly as it could be.
“I believe it’s a wide-open horizon with tremendous potential that needs to be investigated, but there are a number of regulatory hurdles that need to be overcome and that’s where we are,” he said of his study.
A medical study from the University of Colorado Anschutz Medical Campus shows that the anti-inflammatory sensibilities of cannabinoids are the main reason why they may be a potent agent in combating skin diseases.
As part of its guide for healthcare practitioners, Tilray (NASDAQ:TLRY) indicates that medical cannabis could aid patients with inflammatory skin diseases such as dermatitis, psoriasis and pruritus.
“And while this research is still relatively formative, the results achieved so far clearly indicate its value and the promising potential of cannabis as effective medicine,” Tilray wrote.
Dave Berg, chief technology officer for software company Strainprint, told the Investing News Network the lack of sophisticated research has had an impact on the development of novel therapies for patients using cannabis.
“It’s been very difficult for people to study cannabis in a clinical way, but there’s been a ton observational data … There’s no really strong observational data set that allows us to make proper decisions,” Berg said.
In an effort to increase the research options available for cannabis, the Canadian federal government announced plans to spend C$10 million over five years in order to assess the impact of cannabis use on the mental health of Canadians.
Find out what experts say about profiting from the cannabis market in 2020!
Read our FREE 2020 cannabis outlook report!
The government also promised C$10 million to the Canadian Center on Substance Use and Addiction for research purposes.
Skin treatment, either cosmetic or medical, has been one of the many sectors revitalized as new cannabis oil products gain popularity.
These cannabis oil products are developed based on the non psychoactive component of the marijuana plant, CBD.
The introduction of cosmetics with cannabis elements, supported by Canadian licensed producers, is another upcoming element for the skin treatment segment of consumers, and while not medical it does offer more options to the uses of cannabis.
The endorsement from consumers for CBD ointments or other topicals for skincare has been documented with multiple products launched in the fractured US cannabis market.
One downside of the increasing popularity of these products is that it has led companies to make more and more claims about how these items can help with skin conditions. One study from the Journal of the American Medical Association warns that CBD products are often mislabeled online.
Investor takeaway
In order for skin cancer patients to see the potential benefits from treatments with medical cannabis, a lot still has to change in Canada and abroad.
As the medical and recreational sections of the cannabis space continue drifting apart thanks to legalization efforts, the medical space should obtain more time to properly research and investigate the applications of the drug.
The early position CBD has gained in terms of skin maintenance and treatment could lead to further research on its impact with a more serious disease.
What’s more, the given to GW Pharmaceuticals and the increased awareness of the medical benefits for cannabis is moving the needle for how much more research will be put to find out how capable the drug will be in the medical space.
The growth of the cannabis industry has made it possible for companies to offer investment opportunities through the major listing exchanges in Canada.
Previously known as the Canadian Venture Exchange, the TSX Venture Exchange is the sibling listing to the larger Toronto Stock Exchange.
This listing offers a variety of cannabis-related businesses from growers to biotech companies looking for cannabinoid therapies for those interested in investing in cannabis companies.
Find out what experts say about profiting from the cannabis market in 2020!
Read our FREE 2020 cannabis outlook report!
Here the Investing News Network offers investors a growing list of all cannabis-related companies listed on the TSXV.
48North (TSXV:NRTH)
This company is a marijuana producer looking to offer a variety of products for the recreational market in Canada, including for the health and wellness industry. The firm is a licensed outdoor grower of cannabis.
Auxly Cannabis Group (TSXV:XLY,OTCQX:CBWTF)
Founded by Chuck Rifici, Tweed co-founder, Auxly operates as a cannabis streaming investment firm looking to boost various plays related to the sector.
Avricore Health (TSXV:AVCR,OTCQB:AVCRF)
While Avricore operates as a healthcare technology company, in 2017 the firm made a deal with Emerald Health Therapeutics (TSXV:EMH,OTCQX:EMHTF) for the right to develop and sell endocannabinoid products in Canada to licensed pharmacies.
CanadaBis Capital (TSXV:CANB)
This cannabis company is targeting the Canadian market through its business model that is focused on cultivation, research, product development, retail and hemp.
Emerald Health Therapeutics (TSXV:EMH,OTCQX:EMHTF)
This Canadian cannabis company holds a variety of growing assets in the country. The firm holds a 50/50 joint venture for the management of a grower in BC with Village Farms International (TSX:VFF,NASDAQ:VFF).
Find out what experts say about profiting from the cannabis market in 2020!
Read our FREE 2020 cannabis outlook report!
EnWave (TSXV:ENW,OTC Pink:NWVCF)
EnWave is a technology company that has centered itself in the cannabis business thanks to its Radiant Energy Vacuum drying technology for organic materials. It effectively decreases the time from the harvest to the sale of cannabis products.
Elixxer (TSXV:ELXR,OTCQB:ELIXF)
Through its partners, Elixxer presently has significant interests in Australia, Jamaica, Switzerland, Italy and Canada.
Eve & Co. (TSXV:EVE,OTCQX:EEVVF)
Eve & Co. is a Canadian cannabis producer that, thanks to its subsidiary Natural MedCo, is seeking to target women consumers specifically with premier brands.
Experion Holdings (TSXV:EXP,OTCQB:EXPFF)
Formerly known as Viridium Pacific Group, this cannabis investment firm holds a portfolio of assets, including its licensed producer Experion Biotechnologies in Mission, BC.
The Flowr Corporation (TSXV:FLWR,OTC Pink:FLWPF)
Flowr is a vertically integrated cannabis company working on the cultivation and sale of medical and recreational marijuana in Canada.
FluroTech (TSXV:TEST,OTCQB:FLURF)
FluroTech is a technology company working on a cost-effective testing platform for the cannabis industry at large. The company’s proprietary CompleTest employs fluorescence spectroscopy technology to measure the specific contents of the product.
GTEC Holdings (TSXV:GETC,OTCQB:GGTTF)
This Kelowna-based cannabis company is vertically integrated, with operations in the cultivation, extraction and analytical testing sectors. The company is also pursuing retail operations through various investments.
Find out what experts say about profiting from the cannabis market in 2020!
Read our FREE 2020 cannabis outlook report!
Harvest One Cannabis (TSXV:HVT,OTCQX:HRVOF)
Harvest One is a cannabis company with production and assets spread across Canada, Europe, Israel and Australia. The company gains its reach thanks to its three subsidiaries: United Greeneries, Satipharm and Dream Products.
Hill Street Beverage Company (TSXV:BEER)
This beverage maker has made its name thanks to its development of non-alcoholic beverages. Now, the firm will offer consumers cannabis-infused drinks.
INDIVA (TSXV:NDVA,OTCQX:NDVAF)
INDIVA is a company focused on the supply of medical cannabis. Through an acquisition, this company holds a licensed producer with an indoor cannabis facility in Ontario.
Find out what experts say about profiting from the cannabis market in 2020!
Read our FREE 2020 cannabis outlook report!
Khiron Life Sciences (TSXV:KHRN,OTCQB:KHRNF)
Khiron is a Colombia-based cannabis company raising capital in Canada through the TSXV. The firm has declared that it will seek to expand its presence through Latin America, including Mexico.
Meta Growth (TSXV:META)
This company is a retail operator managing cannabis shops across the country. National Access Cannabis manages two recreational store brands: Meta Cannabis Supply and NewLeaf Cannabis.
Find out what experts say about profiting from the cannabis market in 2020!
Read our FREE 2020 cannabis outlook report!
Namaste Technologies (TSXV:N,OTCQB:NXTTF)
After undergoing a tumultuous management change, Namaste has centered back on its investments and development of its marijuana play, which includes its online platform of cannabis consumer information.
Naturally Splendid Enterprises (TSXV:NSP,OTCQB:NSPDF)
Naturally Splendid is a biotech company working on the development of hemp products for consumers in the health and wellness space. The company will pursue a stake in the edible CBD market as well.
Pharmacielo (TSXV:PCLO,OTC Pink:PHCEF)
Pharmacielo is another cannabis company originally from Colombia raising capital in the Canadian markets. The company is headquartered in Canada but operates as part of its marijuana growing in Rionegro, Colombia.
Radient Technologies (TSXV:RTI,OTCQX:RDDTF)
Radient is an extraction technology company that has dabbled in the cannabis sector thanks to a partnership with licensed producer Aurora Cannabis (TSX:ACB,NYSE:ACB).
Relevium Technologies (TSXV:RLV,OTCQB:RLLVF)
Thanks to its subsidiary Biocannabix, this company has a cannabis play in the development of pharmaceutical grade products infused with cannabinoid formulations.
Find out what experts say about profiting from the cannabis market in 2020!
Read our FREE 2020 cannabis outlook report!
SugarBud Craft Growers (TSXV:SUGR)
Like some other Canadian cannabis producers, this Alberta company specializes in growing and developing craft style premium cannabis products.
Target Capital (TSXV:TCI)
Doing business as CBi2 Capital, this Calgary, Alberta based company’s cannabis focused investment strategy focuses on developing and managing a diversified portfolio of predominantly early stage cannabis investment opportunities.
Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF)
Tetra Bio-Pharma is a company working on the research and development of medicines based on cannabis and its elements.
Therma Bright (TSXV:THRM)
Therma Bright is a medical device company that has a subsidiary seeking to carve up a space in the technology space for medical and recreational marijuana thanks to its pain relief device.
WeedMD (TSXV:WMD,OTCQX:WDDMF)
WeedMD is another Canadian cannabis producer making product for the medical and recreational markets in Canada.
YSS (TSXV:YSS)
YSS operates as an adult-use cannabis retailer with 17 stores in Canada.